<DOC>
	<DOCNO>NCT00764907</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . A donor stem cell transplant may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving combination chemotherapy transplant help stop growth cancer cell stop patient 's immune system reject donor 's stem cell . It yet know combination chemotherapy regimen effective treat young patient acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study different risk-adjusted combination chemotherapy regimens treat young patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Risk-Adjusted Combination Chemotherapy Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To test randomized way type intensity reintensification therapy pediatric patient acute lymphoblastic leukemia risk group : standard-risk ( SR ) , intermediate-risk ( IR ) , high-risk ( HR ) group . - To compare two short element reintensification ( protocol III x 2 course ) one ( protocol II x 1 course ) term effectiveness cumulative dose drug regimen patient standard-risk group . - To determine increase risk failure patient intermediate-risk group curtail third reintensification element ( protocol III x 3 course vs protocol II x 1 course ) . - To determine three reintensification element ( protocol III x 3 course ) achieve good result high-risk group patient , compare current apply HR approach Berlin-Frankfurt-Münster Group ( BFM ) Italian Association Pediatric Hematology Oncology ( AIEOP ) . OUTLINE : This partially randomize , multicenter study . Patients stratify accord risk group ( standard risk [ SR ] v intermediate risk [ IR ] vs high risk [ HR ] ) . Patients randomized reinduction part treatment . - Induction therapy : - Protocol I ' ( SR B-cell precursor [ BCP ] ALL ) : Patients receive methotrexate intrathecally ( IT ) day 1 , 12 , 33 ( possibly day 18 27 ) ; prednisone prednisolone orally IV day 1-28 followed taper ; vincristine sulfate IV day 1 , 8 , 15 , 22 , 29 ; daunorubicin hydrochloride IV 1 hour day 8 15 ; asparaginase IV 1 hour day 12 , 15 , 18 , 21 , 24 , 27 , 30 , 33 . Patients receive cyclophosphamide IV 1 hour day 36 64 ; oral mercaptopurine daily day 36-63 ; cytarabine IV continuously day 38-41 , 45-48 , 52-55 , 59-62 ; methotrexate IT day 45 59 . - Protocol I ( SR T-cell ALL , IR , HR ) : Patients receive therapy Protocol I ' except also receive daunorubicin hydrochloride day 22 29 . Approximately 2 week completion induction therapy , patient proceed consolidation therapy . - Consolidation : Patients achieve complete cytomorphologic remission proceed protocol mM protocol M. Patients HR group proceed 3-block consolidation regimen . - Protocol mM ( BCP-ALL ) ( SR IR ) : Patients receive oral mercaptopurine daily day 1-56 ; medium-dose methotrexate IV 24 hour methotrexate IT day 8 , 22 , 36 , 50 ; leucovorin calcium IV every 6 hour day 9 , 23 , 37 , 51 . - Protocol M ( T-cell ALL ) ( SR IR ) : Patients receive mercaptopurine , methotrexate IT , leucovorin calcium protocol mM , also receive high-dose ( HD ) methotrexate IV 24 hour day 8 , 22 , 36 , 50 . - 3-block consolidation regimen ( HR ) : Patients receive 3 regimen blocks 2 week block . Treatment continue absence unacceptable toxicity . - Block HR-1 ' : Patients receive dexamethasone orally IV 3 time daily day 1-5 ; vincristine sulfate IV day 1-6 ; HD methotrexate IV 24 hour day 1 ; leucovorin calcium IV every 6 hour , begin 42 hour start HD methotrexate , 3 dos ; cyclophosphamide IV 1 hour , every 12 hour , day 2-4 ; HD cytarabine IV 3 hour , every 12 hour , day 5 ( 2 dos ) ; asparaginase IV 2 hour day 6 11 ; triple intrathecal therapy ( TIT ) comprise methotrexate , cytarabine , prednisone , 3 time day 1 . - Block HR-2 ' : Patients receive dexamethasone , HD methotrexate , leucovorin calcium , asparaginase block HR-1 ' . Patients receive TIT day 1 ( CNS-negative patient ) twice day 1 5 ( CNS-positive patient ) . Patients also receive vindesine IV day 1 6 ; ifosfamide IV 1 hour , every 12 hour , day 2-4 ; daunorubicin hydrochloride IV 24 hour day 5 . - Block HR-3 ' : Patients receive dexamethasone asparaginase block HR-1 ' ; TIT 3 time day 5 ; HD cytarabine IV 3 hour , every 12 hour , day 1 2 ; etoposide IV 1 hour , every 12 hour , day 3-5 . Approximately 2 week completion consolidation therapy , patient proceed reinduction therapy . - Reinduction ( randomize ) : Patients continuous complete remission proceed protocol II III . Patients SR IR group randomize arm I II ; patient HR group randomize arm II III . - Arm I ( protocol II x 1 course ) ( SR-1 IR-1 ) : Patients receive dexamethasone orally IV day 1-21 followed taper ; vincristine sulfate IV doxorubicin hydrochloride IV 1 hour day 8 , 15 , 22 , 29 ; asparaginase IV 1 hour day 8 , 11 , 15 , 18 ; methotrexate IT day 1 18 . Patients receive cyclophosphamide IV 1 hour day 36 ; oral thioguanine daily day 36-49 ; cytarabine IV continuously day 38-41 45-48 ; methotrexate IT day 38 45 . - Arm II ( protocol III x 2 3 course interim maintenance therapy [ IMT ] ) ( SR-2 , IR-2 , HR-1 ) : Patients receive dexamethasone orally IV three time daily day 1-14 followed taper ; vincristine sulfate IV doxorubicin hydrochloride IV 1 hour day 1 8 ; asparaginase IV 1 hour day 1 , 4 , 8 , 11 . Patients receive cyclophosphamide IV 1 hour day 15 ; oral thioguanine daily day 15-28 ; cytarabine IV continuously day 17-20 24-27 ; methotrexate IT day 17 21 ( day 1 initial CNS involvement ) . Approximately 1 week completion protocol III ( course 1 ) , patient receive IMT 10 week ( SR group ) 4 week ( IR HR group ) describe . Approximately 1 week completion IMT , patient receive protocol III ( course 2 ) . Approximately 1 week completion protocol III ( course 2 ) , patient IR HR group receive IMT another 4 week follow another course protocol III ( course 3 ) 1 week later . - IMT : Patients receive oral methotrexate weekly oral mercaptopurine daily . - Arm III ( HR-2 ) : Patients receive 1 follow regimen accord local practice : - Regimen HR-2A : Patients receive protocol II arm I , rest 1 week receive IMT 4 week . Approximately 1 week later , patient receive another course protocol II . - Regimen HR-2B : Patients receive treatment 3-block consolidation regimen 3 week block . Approximately 3 week later , patient receive protocol II arm I . - Cranial radiotherapy ( CRT ) reinduction : CNS positive patient ( CNS status 3 ) receive CRT completion protocol II ( SR , IR , HR-2B ) first 1.5-2.5 week IMT ( SR , IR , HR-2A ) . SR IR patient T-cell ALL HR patient receive prophylactic CRT time period . Beginning 2 week completion reinduction ( patient HR group also undergo allogeneic stem cell transplantation , describe ) , patient proceed maintenance therapy . - Maintenance therapy ( MT ) : Patients receive oral mercaptopurine daily methotrexate IV weekly . Each patient subgroup ( except HR patient undergo transplantation ) receive MT period bring total week treatment 104 week , follow : - SR : Patients receive MT 74 week ( SR-1 ) 61 week ( SR-2 ) . - IR : Patients receive MT 74 week ( IR-1 ) 57 week ( IR-2 ) . - HR : Patients receive MT 58 week ( HR-1 ) , 62 week ( HR-2A ) , 63 week ( HR-2B ) . Patients BCP-ALL group SR-1 IR-1 also receive methotrexate IT week 4 , 8 , 12 , 16 MT . Patients BCP-ALL group SR-2 receive methotrexate IT week 4 8 MT . - Allogeneic stem cell transplantation ( ASCT ) : Some patient HR group may undergo ASCT ( usually bone marrow , may peripheral blood umbilical cord stem cell ) , ( time reinduction therapy ) begin 3-4 week completion second protocol III ( HR-1 ) , first protocol II ( HR-2A ) , completion 3-block consolidation regimen ( HR-2B ) . - Under 2 year old : Patients receive oral busulfan every 6 hour day -8 -5 , etoposide IV 4 hour day -4 , cyclophosphamide IV 1 hour day -3 -2 , undergo ASCT day 0 . - At least 2 year old : Patients undergo total body irradiation twice daily day -6 -4 receive etoposide IV 4 hour day -3 , undergo ASCT day 0 . Fractionated local radiotherapy , require , administered day -14 -7 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically proven acute lymphoblastic leukemia ( ALL ) No relapse previously unrecognized ALL Patients must meet one follow risk criterion : Standardrisk ( SR ) group meet follow criterion : Blasts &lt; 1,000/μL peripheral blood ( PB ) day 8 Aged 1 &lt; 6 year Initial WBC &lt; 20,000/μL M1 ( 5 % ) M2 ( ≥ 5 % &lt; 25 % ) blast bone marrow day 15 M1 marrow day 33 Intermediaterisk ( IR ) group meet follow criterion : Aged &lt; 1 ≥ 6 year and/or WBC ≥ 20,000/μL Blasts &lt; 1,000/μL PB day 8 M1 M2 marrow day 15 M3 ( ≥ 25 % ) marrow day 15 OR meet SR criterion M3 marrow day 15 M1 marrow day 33 Highrisk ( HR ) group meet ≥ 1 follow criterion : Meets IR criterion M3 marrow day 15 ( SR M3 day 15 ) Blasts ≥ 1,000/μL PB day 8 M2 M3 marrow day 33 Translocation ( 9 ; 22 ) [ BCR/ABL+ ] ( Philadelphia chromosomepositive ) ( 4 ; 11 ) [ MLL/AF4+ ] No secondary ALL PATIENT CHARACTERISTICS : No Down syndrome No major disease prohibits study treatment ( e.g. , severe congenital heart disease ) Not require significant therapy modification owe study therapyassociated complication No complication due intervention No one miss data need differential diagnosis , selection proper therapy arm PRIOR CONCURRENT THERAPY : No steroid cytostatic drug within four week prior start study therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>